Bausch Health Companies Inc. Q2 2025 Earnings Recap

Bausch Health reported robust performance in Q2 2025, achieving 5% revenue growth and a notable 10% increase in adjusted EBITDA, marking the ninth consecutive quarter of growth.

Key Takeaways

• Continued strong growth in Salix and Solta segments, contributing to double-digit revenue and EBITDA increases.
• The completion of a $7.9 billion debt refinancing improves capital structure and extends maturities, enabling strategic flexibility.
• Acquisition agreement for DURECT Corporation aims to leverage expertise in hepatology for alcohol hepatitis treatment development.